Navigation Links
Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Date:4/28/2011

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

http://www.reportlinker.com/p0487249/Advanced-Lung-Cancer-with-EGFR-Mutation-Positive-Adenocarcinoma.html

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:

• Decisions in treatment and tests through disease stages

• Factors influencing their decisions

• Barriers to optimal patient care

• Confidence in treatment

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary - US Oncologist Survey5

Optimizing Treatment of Advanced Lung Cancer:5

Chapter 1: Introduction6

Table 1: Treatment Options in Advanced Lung Cancer6

Chapter 2: Respondent Demographics8

Table 2: Eligibility Criteria for Survey Participation8

Figure 2.1 Gender of Survey Respondents8

Figure 2.2 Years Since Medical School Graduation9

Figure 2.3 Practice Settings9

Figure 2.4 Practices in NCI Cancer Centers10

Figure 2.5 Geographic Settings10

Figure 2.6 Survey Respondents by State's Lung Cancer Mortality11

Figure 2.7 Number of Physicians in Practice Groups12

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen12

Chapter 3: Treatment of an EGFR Mutation Positive Adenocarcinoma13

Figure 3.1 First line chemotherapy regimen13

Figure 3.2 Factors influencing treatment decision14

Figure 3.3 Confidence in treating patient to an optimal outcome16

Figure 3.4 Sequence of treatment choices17

Figure 3.5 Factors influencing treatment decision18

Figure 3.6 Barriers to management of advanced lung cancer20

Chapter 4: Summary23

Appendix A: Survey Instrument24

Companies mentioned

Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis

To order this report:

: Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
3. Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
4. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
5. Reportlinker Adds Forecast Insight: Antibacterials
6. Reportlinker Adds Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
7. Reportlinker Adds European Smart Homes and Assisted Living Market (2010-2015)
8. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
9. Reportlinker Adds Global Respiratory Care Devices Market (2010 - 2015)
10. Reportlinker Adds Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2011
11. Reportlinker Adds Epidemiology: Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):